Biotechnology

Mannkind

Mannkind released FY2026 Q1 earnings on May 6 After-Market (EST), actual revenue USD 90.17 M (forecast USD 102.6 M), actual EPS USD -0.0539 (forecast USD -0.0133)

US Biopharma Company Reports Q1 Revenue Growth of 15%, Driven by Royalties and Furoscix Sales

MannKind Corp Reports Q1 Loss of $1.667 Million

Mannkind to Release FY2026 Q1 Earnings on May 6 After-Market EST, Forecast Revenue USD 105.31 M, EPS USD -0.0014

Mannkind released FY2025 Q4 earnings on February 26 Pre-Market EST, actual revenue USD 111.96 M (forecast USD 99.85 M), actual EPS USD -0.0519 (forecast USD 0.0137)

Mannkind released FY2025 annual earnings on February 26 Pre-Market EST, actual revenue USD 348.97 M (forecast USD 345.56 M), actual EPS USD 0.02 (forecast USD 0.1128)

Manuckey BioMedical Announces Fourth Quarter Losses

Mannkind to Release FY2025 Q4 Earnings on February 26, Pre-Market EST; Forecast Revenue USD 99.85 M, EPS USD 0.0137

MannKind Biomedical INHALE-1ST Study Recruited First Patient

MannKind Corp Receives FDA Approval to Update AFREZZA® Label

Chief People and Workplace Officer of MannKind Corporation Sells Common Stock

MannKind FUROSCIX® On-body Infusor Approved by FDA

MannKind Announces Five New US Patents for FUROSCIX ReadyFlow Autoinjector

Michael Castagna, CEO of MannKind Corp., Reports Disposal of Common Stock

MannKind Corp's VP sells company stocks

MannKind Corp's FUROSCIX ReadyFlow Autoinjector sNDA Accepted by FDA

Wells Fargo Reiterates Buy Rating on MannKind

Mannkind released FY2025 9 Months Earnings on November 5 Pre-Market (EST), with actual revenue of USD 237.01 M and actual EPS of USD 0.07

Mannkind released FY2025 Q3 earnings on November 5 Pre-Market EST, actual revenue USD 82.13 M (forecast USD 80.25 M), actual EPS USD 0.026 (forecast USD 0.0187)

Mannkind to release FY2025 Q3 earnings report on November 5, pre-market EST, with forecasted revenue of USD 80.25 M and EPS of USD 0.0187

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

MNKD

Mannkind fell 7.87% in the night session; BeiGene fell 0.37% in the night session, with a transaction volume of USD 1.49 million; Moderna rose 1.39% in the night session, with a transaction volume of USD 833,000; ADMA Biologics fell 20.44% in the night session, with a transaction volume of USD 244,000

Price Alert

Beigene

Moderna

Adma Biologics

U.S. stock night trading volatility: Mannkind fell 7.87% in night trading, pressured by poor earnings report and market concerns

Earnings Watch

Mannkind | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 90.17 M

Mannkind | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 90.17 M

UTHR

Wedbush analyst Yun Zhong has reiterated a Buy rating for MannKind (MNKD) stock, maintaining an $8 price target. This decision is based on MannKind's expanding role in United Therapeutics' inhaled portfolio and the potential of the ralinepag DPI program. United Therapeutics' exercise of an exclusive option for a second DPI product highlights confidence in MannKind's technology. The report also notes sustained demand for MannKind's capabilities, justifying the Buy rating. H.C. Wainwright also supports this with a Buy rating and an $8 price target.

- Wedbush analyst Yun Zhong maintains a bullish outlook on MannKind (MNKD) stock, issuing a buy rating on April 23.  
- This recommendation is based on MannKind's growing role in United Therapeutics' inhalation product portfolio and the long-term potential of the ralinepag DPI project, which United Therapeutics is advancing.  
- H.C. Wainwright also affirmed a buy rating for the stock with a target price of $8.00, reflecting confidence in MannKind's capabilities and revenue opportunities.

Tip Ranks

United Therap

MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged

CVGI

SKYX

In Wednesday's trading session, BlueLinx Holdings (NYSE:BXC) saw a significant gain of 28.8%, reaching $59.5, following its Q1 earnings report. Other notable gainers included SKYX Platforms (NASDAQ:SKYX) up 26.38%, Commercial Vehicle Group (NASDAQ:CVGI) up 24.17%, and GEO Group (NYSE:GEO) up 23.31%. Conversely, Primoris Services (NYSE:PRIM) experienced a sharp decline of 50.6% to $100.14, along with Limbach Holdings (NASDAQ:LMB) down 35.14% and Phoenix Asia Holdings (NASDAQ:PHOE) down 33.74%.

benzinga_article

Bluelinx

Commercial Vehicle

SKYX Platforms

NANO Nuclear Energy

Skycorp Solar

Primoris

Limbach

Phoenix Asia

Cre8 Enterprise - CL

Globavend

Broadwind

12 Industrials Stocks Moving In Wednesday's Intraday Session

COMP

U.S. stocks rose significantly on Wednesday, with the Dow Jones gaining around 500 points. DaVita Inc (DVA) shares surged 18.9% after reporting better-than-expected earnings and raising its FY26 guidance. Other notable gainers included Entravision Communications (EVC) up 69.1%, Bloomin’ Brands (BLMN) up 39.4%, and MannKind Corp (MNKD) up 36.4%. Flex Ltd (FLEX) and Compass Inc (COMP) also saw substantial increases following positive quarterly results. Overall, many companies reported strong financial performances, contributing to the market's upward trend.

Entravision Comm

DaVita

Compass

Bloomin Brands

Flex

iShares Genomics Immunology and Healthcare ETF

VG Health

iShares Global Healthcare

iShares US Healthcare Providers

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

SPDR S&P Health

Dow Jones Industrial Average

Hut 8 Mining

Avalo Therapeutics

Veracyte

SSR Mining

International Flavors & Fragrances

Veeco Instruments

Super Micro Computer

Livanova

Healthpeak Properties

Pan American Silver

Corning

NVIDIA

Disney

NVIDIA Corporation

Davita, Bloomin' Brands, Compass And Other Big Stocks Moving Higher On Wednesday

MannKind shares are trading higher after the company announced that its development of a dry powder inhalation version of ralinepag with United Therapeutics will yield milestone payments and royalties.

Mannkind(MNKD.US)